Myasthenia Gravis Market in Quarter 3 2025 Showed a Strong Focus on Access, Education, and Support

Throughout Q3 2025, companies in the myasthenia gravis market announced an approval, financial and clinical trial results, education, and support

Johnson & Johnson highlighted Imaavy’s approval and availability, emphasizing durability as a core message. Additional materials focused on post-approval education and outlined treatment delivery, access, affordability, and coordinated support through Imaavy withMe.

Argenx positioned Vyvgart as a leading biologic in generalized myasthenia gravis, emphasizing leadership, broader patient reach, and growing prescriber adoption. Materials highlighted education, data transparency, and centralized patient support through My Vyvgart Path.